Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$370,642
-$1,194,320 QoQ
Shares Held
2,365
-83.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.25%
of 13F equity value
Holder Rank
#1,023
of 1,603 holders
Holding Since
Sep 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bayesian Capital Management, LP holds $5,153,335 across 7 Drug Manufacturers - General names. NVS ranks #6 (7.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
9,100 | $1,149,694 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
19,200 | $1,106,304 | |
| 3 | GSK |
GSK plc
|
18,100 | $948,802 | |
| 4 | AMGN |
Amgen Inc
|
2,384 | $863,294 | |
| 5 | NVO |
Novo Nordisk A S
|
8,500 | $407,490 | |
| 6 | NVS |
Novartis AG
This page
|
2,365 | $370,642 | |
| 7 | SNY |
Sanofi
|
7,199 | $307,109 |
All Filings in NVS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $370,642 | 2,365 | Shares | Sole | 2026-08-14 | |
| 2024-06-30 | $1,564,962 | 14,700 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $1,025,338 | 10,600 | Shares | Sole | 2024-05-15 | |
| 2023-03-31 | $1,544,956 | 16,793 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $3,319,716 | 36,593 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $2,051,737 | 26,993 | Shares | Sole | 2022-11-14 | |
| 2022-03-31 | $1,458,141 | 16,617 | Shares | Sole | 2022-05-16 | |
| 2020-09-30 | $627,242 | 7,213 | Shares | Sole | 2020-11-12 | |
| No filing history on record for this holder in this stock. | ||||||